ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Who Writes NCI’s bypass Budget anyway>? Editor’s name Revealed

May 14, 1993

DCPC Board Approves Concepts For New Master Agreement, Recompetitions

October 9, 1987

In Brief: Columbia-Presbyterian Cancer center to Be Renamed After Donor Herbert Irving

December 6, 1996

Allegations Reflect Misunderstanding, Pan Data Says

August 4, 1989

After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk

December 13, 2002

NCI Advisors Approve $20.5M Program Of Grants, Contracts For Biospecimen Research.

July 6, 2007